Johnson Matthey Plc · LSE:JMAT
Johnson Matthey — Investor Presentation (October 2018)
16 slides from Johnson Matthey's investor presentation, Oct 5, 2018
Slide 1: Sector call – Health
Sector call – Health 5th October 2018 Jason Apter Chief Executive, Health
Slide 2: Cautionary statement
Cautionary statement This presentation contains forward looking statements that are subject to risk factors associated with, amongst other things, the economic and business circumstances occurring from time to time in the countries and sectors in which Johnson Matthey operates. It is believed that t
Slide 3: Introduction
Introduction • Joined Johnson Matthey in March 2018 • Previous roles in finance, business transformation, product management and corporate strategy & development • Most recently worked for Merck KGaA • Experience across a variety of industry segments • Extensive experience in driving innovation, gro
Slide 4: History of our Health sector
History of our Health sector 1970’s 1980’s 2001 2015 Pgm based molecules Expansion into Acquisition of Acquisition of Pharmorphix for cancer treatment controlled substances Macfarlan Smith (UK) and developed Pharm-Eco (US) Expertise in pgm chemistry Utilising expertise in supply Established as globa
Slide 5: Our Health sector today
Our Health sector today Focus on development Proven and track Expertise manufacturing 2017/18 of high | Sales £247m| across OP £44m generic and record with capability Focus on development and manufacturing quality, complex APIs over time innovator customers developed Innovator: of high quality, comp
Slide 6: JM wins through science and its application
JM wins through science and its application Innovators and generics Value chain Development Scale-up Manufacture JM’s competitive Materials design, development Process chemistry and Process engineering and advantage and characterisation flexible high quality capacity manufacturing excellence Example
Slide 7: Outsourced small molecule API market is growing at 8% p.a.
Outsourced small molecule API market is growing at 8% p.a. Global sales in API An attractive segment which plays to $170bn 1 our strengths Generics Outsourced small $29bn Complex chemistry molecule APIs 9% growth p.a. More targeted and potent APIs - Increasing complexity Outsourced large of APIs and
Slide 8: Key focus areas to deliver breakout growth
Key focus areas to deliver breakout growth Enhancing the performance of our existing business Expanding our new product pipeline and portfolio Building our capabilities to better support our customers for future growth 8
Slide 9: Enhancing the performance of our existing business
Enhancing the performance of our existing business New sales opportunities APIs being expanded into new generic filings Growth through footprint optimisation (more capacity) Operational efficiency Strategic sourcing Manufacturing excellence 9
Slide 10: Expanding our new product pipeline and portfolio
Expanding our new product pipeline and portfolio Focus on both Utilising same generics and innovators resources and skills Generics Innovators Focus on complex molecules Increasing complexity in new drugs utilises our key competences Diverse and robust pipeline Support customers through from to deli
Slide 11: Building our capabilities to better support our customers for future growth
Building our capabilities to better support our customers for future growth Globalise our Build out particle Improve development technology understanding of capabilities expertise drug formulation 11
Slide 12: Health sector to deliver break out growth
Health sector to deliver break out growth Well positioned in an attractive market Leverage Johnson Matthey core competences Strong product pipeline Double-digit growth beginning in 2019/20, with margins increasing to high 20%s 12
Slide 13: Q&A
Q&A
Slide 14: Appendix
Appendix
Slide 15: Generics example: development of dofetilide
Generics example: development of dofetilide Developed an innovative Significant financial Additional generic Development and non-infringing route contribution in competition - started in 2011 & polymorph 2016/17 summer 2018 Utilised solid form Partner launched in June 2016 JM shares drug sciences an
Slide 16: Innovators example: Customers come to JM for expertise
Innovators example: Customers come to JM for expertise JM begins work on Customer Customer A New 5 year API 1 with A awards awards API 6 commercial supply Customer A and Commercial and extension agreement signed awarded contracts Supply Agreement of API 5 with Customer A for API 2 and API 3 for API
Johnson Matthey — Investor Presentation (October 2018) on 6ix